Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
BLCAP
REST API REST API
Homo sapiens
BLCAP is differentially expressed in 277 experiments: 115 organism parts: amygdala, hypothalamus, ... (113 more);, 176 disease states: normal, acute myeloid leukemia, ... (174 more);, 75 cell types 383 cell lines 38 compound treatments and 68 other conditions.
Synonyms BC10
Orthologs Blcap (Rattus norvegicus)   blcap (Danio rerio)   BLCAP (Gallus gallus)   Blcap (Mus musculus)   blcap (Ciona intestinalis)   BLCAP_BOVIN (Bos taurus)   bc10 (Drosophila melanogaster)   blcap (Xenopus laevis)   (Compare orthologs)
Gene Ontology Term protein binding, apoptosis, membrane, cell cycle, integral to membrane
InterPro Term BC10-like
UniProt Accession P62952, A2A2K9, A2A2K8
Search EB-eye ENSG00000166619
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-AFMX-5, E-GEOD-6573, E-MEXP-1251, E-MTAB-24, ... (24 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-MEXP-1006, E-GEOD-19639, E-GEOD-18005, ... (45 experiments)

Factor Value U/D Experiments
BT474
3
E-MTAB-37, E-MEXP-440, E-MTAB-62
MCF-7
3
E-GEOD-20081, E-GEOD-19639, E-GEOD-3529
SW480
3
E-MEXP-1014, E-GEOD-18005, E-GEOD-2509
HCC1937
2
E-MTAB-37, E-MTAB-62
SKBR3
2
E-MEXP-440, E-MTAB-62
PC3
1
2
E-GEOD-5258, E-MEXP-2034, E-GEOD-14464
377 more value(s).


Cell type

studied in E-GEOD-22529, E-GEOD-21668, E-GEOD-19397, E-GEOD-3920, E-GEOD-360, ... (41 experiments)

Factor Value U/D Experiments
dendritic cell
2
E-GEOD-3982, E-GEOD-360
stromal cell
2
E-MEXP-2034, E-GEOD-10797
CD19+ B cell
1
E-MEXP-1600
germ cell
1
E-MTAB-25
plasmacytoid dendritic cell
1
E-TABM-34
white blood cell
1
E-GEOD-2006
69 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-16363, E-MTAB-62, E-GEOD-5370, ... (56 experiments)

Factor Value U/D Experiments
colon carcinoma
3
E-MTAB-62, E-MTAB-37, E-GEOD-3726
control
3
E-GEOD-21912, E-GEOD-8121, E-GEOD-16363
glioblastoma
3
E-GEOD-4290, E-GEOD-6014, E-MTAB-62
prostate carcinoma
2
E-MEXP-2034, E-GEOD-96
alveolar rhabdomyosarcoma
2
E-MTAB-62, E-MEXP-121
dermatomyositis
2
E-MTAB-62, E-GEOD-5370
170 more value(s).


Compound treatment

studied in E-GEOD-6907, E-GEOD-5741, E-GEOD-1417, E-TABM-782, E-GEOD-697, ... (23 experiments)

Factor Value U/D Experiments
interferon alpha
1
E-GEOD-1740
actinomycin D
1
E-GEOD-6400
control
1
E-GEOD-3284
sapphyrin PCI-2054
1
E-GEOD-6400
placebo
1
E-MEXP-1335
U0126
1
E-GEOD-697
32 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519


Biopsy tissue
studied in E-GEOD-5851

Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Clinical history
studied in E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-GEOD-21589, E-GEOD-16363, ... (6 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-MEXP-1251, E-GEOD-19246, ... (10 experiments)

Clinical treatment
studied in E-GEOD-6532, E-GEOD-21610

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-1614, E-GEOD-20033, E-GEOD-3140, E-MEXP-2359, E-GEOD-6236, ... (6 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-2509, E-GEOD-22148, E-TABM-147

Environmental stress
studied in E-GEOD-1518

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-8023, E-GEOD-7578, E-GEOD-20847, E-MEXP-563

Genotype
studied in E-GEOD-1923, E-MEXP-1437, E-GEOD-3494, E-GEOD-17476, E-GEOD-2292, ... (10 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-MEXP-1220, E-TABM-127, E-MEXP-1446, E-GEOD-22278, ... (9 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276

Individual
studied in E-MTAB-197, E-TABM-325, E-GEOD-1926, E-MEXP-2069, E-GEOD-16363, ... (31 experiments)

Infection
studied in E-GEOD-2405, E-GEOD-12108, E-MEXP-561, E-GEOD-980

Injury
studied in E-GEOD-19743

Irradiate
studied in E-GEOD-1977, E-TABM-321

Karyotype
studied in E-GEOD-22056

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Material type
studied in E-MEXP-455, E-MEXP-958

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540, E-GEOD-1801, E-GEOD-426, E-TABM-84

Organism status
studied in E-GEOD-19188

P53 ihc
studied in E-GEOD-21653

Performer
studied in E-LGCL-5

Phenotype
studied in E-GEOD-19703, E-GEOD-22152, E-GEOD-22309, E-GEOD-6434, E-GEOD-1657, ... (7 experiments)

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-1880, E-GEOD-19445, E-GEOD-1343, ... (6 experiments)

Replicate
studied in E-GEOD-10896

RNAi
studied in E-MEXP-1509, E-GEOD-1676, E-MEXP-101, E-GEOD-3697, E-MEXP-1857 ... (5 experiments)

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-17400

Sex
studied in E-GEOD-7307

Stimulation
studied in E-GEOD-4883, E-GEOD-20114, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-16837, E-GEOD-21909, E-GEOD-19246, E-GEOD-19815, E-GEOD-15799, ... (6 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-1561, E-TABM-147

Processing time: 0.335 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM